Surv BioPharma
$9.8M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Surv BioPharma is currently valued at $28.8M as of November 11, 2025. The company has raised a total of $17.2M in funding.
Capital Efficiency
With a capital efficiency ratio of 1.68x, Surv BioPharma has achieved a valuation that is 1.68 times the total capital raised. This metric indicates room for improvement in capital deployment.
Investment Perspective
Surv BioPharma's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Surv BioPharma Worth in 2025?
As of 2025, Surv BioPharma is valued at $28.8M, based on the company's Early Stage VC funding round in November 11, 2025. This valuation positions Surv BioPharma as one of the leading private companies in the sector.
Surv BioPharma Valuation History
Surv BioPharma's funding history demonstrates steady growth and investor confidence.
How Surv BioPharma Valuation is Determined
Private company valuations like Surv BioPharma's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Surv BioPharma Valuation FAQs
Is Surv BioPharma profitable?
Surv BioPharma has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Surv BioPharma's valuation compare to competitors?
Surv BioPharma is valued at $28.8M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Surv BioPharma IPO?
Surv BioPharma has not announced plans for an initial public offering. Until an IPO, investors can access Surv BioPharma shares through secondary market platforms.